LSI

Limaca Medical Ltd's (LSI Europe ‘24 Innovator) vision is to ensure that endoscopic biopsies always achieve a definitive diagnosis to enable optimal and timely cancer treatment. Limaca’s Precision GI™ device’s motorized, automated, rotating cutting mechanism allows greater tissue acquisition with less blood content, in a single pass, saving critical procedure time and effort. Today’s endoscopic biopsy devices have limitations in consistently obtaining quality tissue of sufficient quantity; this can result in sample tissue fragmentation, inadequate tissue volume, and blood contamination. Limaca Medical’s Precision GI™ obtains biopsy tissue for definitive diagnosis of pancreatic cancer and other life-threatening GI cancers more quickly and less traumatically than current products. The automated device is designed to allow more efficient and effective diagnosis of GI cancers by yielding significantly superior quality and quantity of diagnostically relevant biopsy tissue. Limaca has reached significant milestones, including: • Raised equity funding from international investors alongside non-dilutive grants; now raising Series A • Strong patent portfolio, multiple IP families. Biopsy device patent granted in multiple major markets • Completed >60 clinical cases internationally • Received FDA Breakthrough & 510(k) clearance • Japan registration in process with Japanese distribution partner • Commercial manufacturing capability established • In the final stage of preparing to launch Precision GI in the USA during Q4. We’re excited to announce that CEO, Assaf Klein has been selected to present Limaca Medical at LSI Europe ‘24 this September 16-20th in Sintra, Portugal. Join us in Portugal to meet with Assaf and learn more about Limaca Medical.

“The job of a CEO is to raise money, and then get a return on that money.” For Duke Rohlen and the Ajax Health team, every investment decision begins with an assessment of the company's strategy. Before diving into the details of technology, operations, or management, they need to know how the company is going to create liquidity. As market conditions evolve, the ability to identify and execute on multiple pathways to monetize a business—whether through partnerships, roll-ups, or private equity funding—has become essential. CEOs who prioritize these strategies are better equipped to navigate the complexities of today’s market, positioning their companies for sustained growth and successful exits. Catch the full panel, “Medtech Buyouts by Private Equity” now available on our website and YouTube channel. Featured Panelists: • David Uffer (Moderator) — Trinity Life Sciences • Antonio Sánchez-Cordero — ARCHIMED • Duke Rohlen — Ajax Health • Erich Wolff — Partners Group You can hear more from Duke Rohlen, CEO and Managing Director of Ajax Health, at LSI Europe '24 where he will be giving a Keynote Presentation based on his recently published thesis, "The Middle Path to Innovation," published in the Harvard Business Review. He will discuss strategies for developing high-growth products in slow-growth companies and present the growth driver model—a framework that partners corporations with external investors to identify and develop innovation opportunities, drawing on corporate resources and talent and externally recruited entrepreneurs.

Melodi Health (#LSIAlumni) raised a $10.75M oversubscribed Series A funding round with investors including HM Venture Partners, Engage Venture Partners, Southeast Minnesota Capital Fund, and Three Bridges Private Capital. The company also announced the launch of the "ARIA" investigational device exemption (IDE) trial aimed at improving clinical outcomes for women undergoing breast reconstruction after mastectomy. Today, there are no FDA-approved soft tissue support products for use in breast surgery, and none that contain antibiotics. The Absorbable Antibacterial Soft Tissue Support in Breast Reconstruction with Infection Outcomes Assessment (ARIA) clinical trial is a multicenter, nationwide, randomized, controlled study evaluating the safety and efficacy of the Melodi Matrix™ to support an FDA Approval for an indication in breast reconstruction. The Melodi Matrix, an absorbable mesh that is designed to support soft tissue while providing controlled release of antibiotic agents as it is absorbed into the body, is an implantable medical device comprised of proprietary technology licensed from Medtronic by Melodi Health. Congratulations to LSI Alumni Sarah Worrell, and the entire Melodi Health team on the recent success. We look forward to following your progress.

Despite the challenges and uncertainties in today’s financial landscape, there are signs of hope emerging in Medtech financing. Companies that can navigate the complexities of the current market may find new opportunities and sources of capital that can drive innovation and growth. In our upcoming LSI Europe ‘24 panel, "Light at the End of the Tunnel in Medtech Financing," we’ll explore the positive developments and potential pathways that are beginning to emerge. This discussion will highlight emerging opportunities, successful strategies for raising capital, and what these developments mean for the future of Medtech. We’ll hear perspectives from: • Nick Pachuda (Moderator) — Precision Life Science Partners • Martin Omid A. — Anthro Ventures • Anita Watkins — Rex Health Ventures • Sean Morris — Cultivation Capital • Eman Namati — SpectraWAVE, Inc. Join us at LSI Europe ‘24 this September 16-20th to see more panel sessions like this and connect with hundreds of global Medtech and Healthtech leaders in Sintra, Portugal. Apply on our website today while space is still available.

As economic uncertainty looms and traditional funding sources tighten, the Medtech industry faces a critical question: where will the capital and liquidity necessary for growth come from? In our upcoming LSI Europe ‘24 panel, "Medtech's Conundrum: Where Will Capital and Liquidity Come From?" we’ll explore the evolving funding landscape and perspectives on the health of the ecosystem at large. This discussion will bring together industry leaders and investors to provide insights into seed and growth financing, emerging trends, and the future of capital raising in Medtech. We’ll hear perspectives from: • Michael Wasserman (Moderator) — Elevage Medical Technologies • Diana Saraceni — Panakes Partners • Alexander Schmitz — Endeavour Vision • David Kereiakes — Windham Capital Partners Join us at LSI Europe ‘24 this September 16-20th to see more panel sessions like this and connect with hundreds of global Medtech and Healthtech leaders in Sintra, Portugal. Apply on our website today while space is still available.

Peregrine Ventures (LSI Europe ‘24 Investor) is dedicated to supporting and advancing medical innovation through strategic investments. The Peregrine advantage brings together deep industry knowledge and an embedded synergetic strategy. This allows their team of investment professionals to support their portfolio companies in the development of meaningful breakthroughs in healthcare. Whether at an early-stage seed or advanced growth stage, Peregrine’s synergetic approach to investing reaches beyond capital. This allows the firm to provide expert, focused, and concrete services throughout the company lifecycle. Different stages of growth, require different levels of support, and in order to provide that support, Peregrine has created specifically defined funds: 1. Peregrine’s ‘Incentive’ Incubator: This fund allows for investments in pre-seed companies where their team can help turn a creative idea into an innovative company. Through this vehicle, Peregrine provides incubator companies with the technological infrastructure, financial management, business development support, strategic planning, and assistance in team recruitment that results in successful companies. 2. The Peregrine Fund: Focuses on investments in early and mid-stage companies. In this vehicle, we work closely with entrepreneurs at the early-stage of business and product development, providing them with the tools and knowledge needed to take their company to the next level – from research and development to regulatory, reimbursement, and business operations. 3. The Peregrine Growth Fund: Seeks to assist more mature companies that have the potential to provide outstanding returns withing a short time frame at low risk. Through deep industry connections, they help late-stage companies in their last rounds of financing prior to M&A or IPO. Peregrine Ventures portfolio includes companies like: • Nitinotes Surgical (LSI Alumni - Lloyd Diamond) • CartiHeal (Nir Altschuler) • Conair Medical (Aviad Galler) • Momentis Surgical™ (Dvir Cohen) • among others We’re excited to welcome Boaz Lifschitz, Co-Founder & Managing General Partner, and Lior Shahory, General Partner at Peregrine Ventures to LSI Europe ‘24 on September 16-20th in Sintra, Portugal. Want to see what other investors are joining us at LSI Europe ‘24? Head over to our website to see a preview of 200+ confirmed investors and strategics.

“It’s important for you to be very thoughtful about who you invite onto the board, what their motivations are, what they’re incentivized by. People behave around incentives and bias, and understanding that can help you build a good board.” The full LSI USA '24 panel, “Human Capital: Challenges and Solutions in Retention and Scalability” is available on our website and YouTube channel. Tune into the full video recording to hear from a diverse group of innovators, investors, and talent acquisition experts who have built amazing teams from the ground up and have decades of experience matching companies with the right talent. The panelists discussed the secrets to top-performing teams, the challenges and solutions to retaining great talent, scaling up effectively, and much more. Featured panelists: • Charles Rohaut — ZRG Partners, LLC • Alex Bennett — ZRG Partners • Jeff Mollica — ZRG Partners • Evan Luxon — Centese • David Kereiakes — Windham Capital Partners

“Data and AI are oftentimes thrown in together as a consolidated buzzword but they really are two independent entities. AI does not drive change management, but data does. As we’re talking about unmet needs and the landscape, I think that’s a really important distinction to keep in mind.” - Dr. Janani Reisenauer, Vice Chair Surgery Innovation, Mayo Clinic During #LSIUSA24, this panel of senior leaders from GE Healthcare, Intuitive, Mayo, SANTÉ, and Veranex shared insights on the latest advancements in digital surgery, investment trends, and what this means for the future of the industry. Tune into the full panel, “Future of Digital Surgery, with Senior Leaders from GE HealthCare, Intuitive, Mayo, SANTE, & Veranex”, to hear perspectives from: • Lisa Carmel (Moderator), EVP Global Strategic Partnerships, Veranex • Brian Miller, EVP & Chief Digital Officer, Intuitive • Janani Reisenauer, Vice Chair Surgery Innovation, Mayo Clinic Rochester • Philip Rackliffe, President & CEO - Image Guided Therapies, GE HealthCare • Dennis McWilliams, Partner, SANTÉ Join us at LSI Europe ‘24 this September 16-20th to see more panel sessions like this and connect with hundreds of global Medtech and Healthtech leaders in Sintra, Portugal. Apply on our website today while space is still available.

When it comes to securing investment, understanding why some investors pass on opportunities is key to refining your approach. Investment mandates, risk tolerance, and differing views on success play significant roles in these decisions. Gaining insight into these factors can help Medtech companies better align their strategies with investor expectations. In our latest LSI Europe '24 panel, "Investors That Pass: An Open Dialogue on Investment Mandates and Definitions of Success," we’ll engage with investors who will openly discuss the factors that lead them to pass on certain opportunities. This panel will provide an inside look at how different investors define success and what truly drives their investment decisions. We’ll hear perspectives from: • Alexei Mlodinow (Moderator) — SIA (Acquired by Integra LifeSciences)) • Diana Saraceni — Panakes Partners • Dr. Irit Yaniv — Almeda Ventures Join us at LSI Europe ‘24 this September 16-20th to see more panel sessions like this and connect with hundreds of global Medtech and Healthtech leaders in Sintra, Portugal. Apply on our website today while space is still available.

EP Solutions (LSI Europe '24 Innovator) is improving clinical outcomes in cardiac resynchronization therapy cases through the use of noninvasive cardiac mapping technology. The company's Amycard 01C is an electrophysiology workstation that records body surface electrograms to create optimized 3D heart models that merge ECG data with anatomical data obtained from medical imaging. EP Solutions' technology helps physicians accurately place CRT leads during implantation and optimize devices during follow-up visits. The company has made significant strides recently, achieving milestones such as: • Successfully raised a €4 million funding round that will drive two key initiatives: (1) multicenter, randomized and controlled study ICONIC-M, currently enrolling patients; and (2) the development of CRiTeria, the second-generation noninvasive planning system for cardiac resynchronization therapy. • Began enrollment in their pivotal clinical study, ICONIC-M, with 20 patients already participating out of the planned 376. The study objectives are to evaluate whether pre-acquired ECGi map-guided LV lead placement improves CRT response and to assess the reduction in distance to LV LEAS (latest electrically activated site) when using Amycard ECGi mapping, compared to non-guided LV lead placement. We’re excited to announce that CEO, Marcin Gołębicki has been selected to present EP Solutions at LSI Europe ‘24 this September 16-20th in Sintra, Portugal. Join us in Portugal to meet with Marcin and learn more about EP Solutions.